All issues
Volume 23 (2008)
- Issue 6 Pages 610-
- Issue 5 Pages 518-
- Issue 4 Pages 448-
- Issue 2 Pages 112-
- Issue 1 Pages 24-
Volume 23, Issue 2
Displaying 1-7 of 7 articles from this issue
- |<
- <
- 1
- >
- >|
Feature articles “Vaccine in DDS” Editor : Shinsaku Nakagawa
-
Shinsaku Nakagawa, Naoki Okada2008 Volume 23 Issue 2 Pages 112-115
Published: 2008
Released on J-STAGE: June 18, 2008
JOURNAL FREE ACCESSCharacteristics of various virus, germs and tumor cells have been identified following the recent development of molecular biology. Because those results are reflected by immunology, a novel vaccine strategy for an infectious disease and tumor has been developed. Vaccine is also developed as not only prophylactic medicine but also a remedy. In this review, I introduce the vaccine for infectious disease and cancer.View full abstractDownload PDF (211K) -
Jun Kunisawa, Hiroshi Kiyono2008 Volume 23 Issue 2 Pages 116-122
Published: 2008
Released on J-STAGE: June 18, 2008
JOURNAL FREE ACCESSMucosal vaccine has been considered to be a novel prospective vaccine against infectious diseases (e.g., influenza and infectious enteritis) because it can induce double layered protective immunity through both mucosal and systemic immune systems. Recent advances in DDS technology and progresses in cellular and molecular understanding of the mucosal immune system allow us to overcome several problems in the development of mucosal vaccine.
Especially, DDS not only protects antigen from harsh conditions of the mucosal environment but also delivers antigen efficiently to mucosa-associated lymphoid tissue (MALT) including Peyer's patches and nasopharynx-associated lymphoid tissue (NALT), initiation sites for the antigen-specific immune response. In this review, we shed light on the dynamics of mucosal immune system and recent achievements toward the development of DDS-based mucosal vaccine.View full abstractDownload PDF (336K) -
Ryo Suzuki, Yusuke Oda, Naoki Utoguchi, Norimitsu Kadowaki, Kazuo Maru ...2008 Volume 23 Issue 2 Pages 123-129
Published: 2008
Released on J-STAGE: June 18, 2008
JOURNAL FREE ACCESSIn cancer immunotherapy with dendritic cells(DCs), which are the most potent antigen-presenting cells, it is important that DCs present peptides derived from tumor-associated antigens on major histocompatibility complex(MHC) class I molecules and activate tumor-specific cytotoxic T lymphocytes. However, exogenous antigens are generally presented on MHC class II but not class I molecules. To induce the effective immunotherapy for cancer, it is necessary that the antigen delivery carrier which can induce MHC class I presentation of exogenous antigens is developed.
Several strategies to induce DCs to present exogenous antigens on MHC class I have been reported. First, DCs that phagocytosed a particulate form of antigens present peptides derived from the antigens on MHC class I. Second, DCs that incorporated antigens via certain endocytic receptors such as Fcγ receptors efficiently present peptides on MHC class I. Thus, we combined these two strategies and prepared the antigen-containing IgG-conjugated liposomes(IgG liposomes). In this review, we introduced about the feasibility of IgG liposomes as the antigen delivery carrier in cancer immunotherapy with DCs.View full abstractDownload PDF (502K) -
Keisuke Matsuo, Tomoaki Yoshikawa, Naoki Okada, Shinsaku Nakagawa2008 Volume 23 Issue 2 Pages 130-137
Published: 2008
Released on J-STAGE: June 18, 2008
JOURNAL FREE ACCESSEstablishment of the technique capable of delivering tumor-associated antigen(TAA) to antigen-presenting cells efficiently is expected to improve efficacy of tumor vaccine therapy. We succeeded in augmentation of tumor immunity based on efficient induction of the cytotoxic T cells specific for TAA by applying poly(γ-glutamic acid)-based nanoparticles (γ-PGA NPs) as antigen delivery carriers. In this review, we give an outline about a utility of nanoparticle DDS technology in tumor vaccine therapy, mainly on our data using γ-PGA NPs.View full abstractDownload PDF (739K) -
Shigeru Kawakami, Yuriko Higuchi, Hideyuki Nakanishi, Yukari Kuramoto, ...2008 Volume 23 Issue 2 Pages 138-144
Published: 2008
Released on J-STAGE: June 18, 2008
JOURNAL FREE ACCESSIncreased understanding of the molecular pathological mechanisms of tumor, the progress of novel nucleic acids such as CpG oligonucleotides as a strong adjuvant or plasmid DNA(pDNA) encoding tumor-related antigen have provided an encouraging perspective for tumor immunotherapy. Since naked CpG oligonucleotide or pDNA has less therapeutic effect because of their less stability in the body and little accumulation to the immune cells as a target cells, a technology for the in vivo delivery of nucleic acids to immune cells has been necessary. In this review, we will introduce of the tumor immune mechanism and immune cells targeted delivery of nucleic acids for tumor immunotherapy using liposomes.View full abstractDownload PDF (386K) -
WT1 peptide-based cancer immunotherapyHaruo Sugiyama2008 Volume 23 Issue 2 Pages 145-150
Published: 2008
Released on J-STAGE: June 18, 2008
JOURNAL FREE ACCESSWilms' tumor gene WT1 is overexpressed in leukemias and almost all types of solid tumors, and exerts an oncogenic function in leukemogenesis and tumorigenesis. WT1 protein is a pan-tumor associated antigen and we performed for the first time the WT1-peptide-based cancer immunotherapy and demonstrated its safety and clinical effect.View full abstractDownload PDF (484K) -
Koichi Yamanishi2008 Volume 23 Issue 2 Pages 151-158
Published: 2008
Released on J-STAGE: June 18, 2008
JOURNAL FREE ACCESSIt is really expected to develop vaccines which are based on newly developed technologies, since we are facing to various emerging infectious diseases such as new influenza epidemic. Various vaccines for infants or children have been developed to use, but vaccines for adolescent such as human papilloma vaccine, and those for adults such as zoster vaccine have been recently developed in USA and Europe. Vaccines based on new concept such as recombinant vaccine, DNA vaccine, polypeptide vaccine and mucosal vaccine will be on market in near future. Furthermore, development of new adjuvants inducing high immunity but having few side-reaction is urgently needed.View full abstractDownload PDF (415K)
- |<
- <
- 1
- >
- >|